<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8163">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000673</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-010</org_study_id>
    <nct_id>NCT03000673</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis</brief_title>
  <official_title>A Study to Assess Safety and Tolerability of Single Oral Doses of BMS-986177 in Patients With ESRD Treated With Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety of Single Doses of BMS-986177 in Patients with End Stage Renal Disease
      treated with hemodialysis
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 25, 2017</start_date>
  <completion_date type="Anticipated">February 14, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 13, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Adverse events (AEs)</measure>
    <time_frame>Up to 45 Days</time_frame>
    <description>Measured by number of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in clinical laboratory values</measure>
    <time_frame>Day -3 to Day 15</time_frame>
    <description>Measured by laboratory assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in vital signs assessment</measure>
    <time_frame>Day -3 to Day 15</time_frame>
    <description>measured by investigator assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in Electrocardiogram (ECG) assessment</measure>
    <time_frame>Day -3 to Day 12</time_frame>
    <description>Measured by investigator assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Approximately 15 Days</time_frame>
    <description>Measured by laboratory assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Approximately 15 Days</time_frame>
    <description>Measured by laboratory assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysate clearance of drug from plasma/serum (CLD)</measure>
    <time_frame>Approximately 15 Days</time_frame>
    <description>Measured by laboratory assay</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Antithrombotic</condition>
  <arm_group>
    <arm_group_label>Dose Sequence 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Sequence 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Sequence 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Sequence 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Specified dose of Enoxaparin on specified days</description>
    <arm_group_label>Dose Sequence 1</arm_group_label>
    <arm_group_label>Dose Sequence 2</arm_group_label>
    <arm_group_label>Dose Sequence 3</arm_group_label>
    <arm_group_label>Dose Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unfractionated heparin (UFH)</intervention_name>
    <description>Specified dose of UFH on specified days</description>
    <arm_group_label>Dose Sequence 1</arm_group_label>
    <arm_group_label>Dose Sequence 2</arm_group_label>
    <arm_group_label>Dose Sequence 3</arm_group_label>
    <arm_group_label>Dose Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177</intervention_name>
    <description>Specified dose of BMS-986177 on specified day</description>
    <arm_group_label>Dose Sequence 1</arm_group_label>
    <arm_group_label>Dose Sequence 2</arm_group_label>
    <arm_group_label>Dose Sequence 3</arm_group_label>
    <arm_group_label>Dose Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects with ESRD treated with hemodialysis 3 times a week for at least 3 months
             prior enrollment.

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior
             to the start of study treatment.

          -  Women must not be breastfeeding

          -  Women of childbearing potential (WOCBP) must agree to follow instructions for
             method(s) of contraception for the duration of treatment with study treatment(s)
             BMS-986177 plus 5 half-lives of study treatment (2 days) plus 30 days (duration of
             ovulatory cycle) for a total of 32 days post-treatment completion

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment with study treatment(s)
             BMS-986177 plus 5 half-lives of the study treatment plus 90 days (duration of sperm
             turnover) for a total of 92 days post-treatment completion. In addition, male
             participants must be willing to refrain from sperm donation during this time.

        Exclusion Criteria:

          -  Subjects receiving dialysis through central venous catheters

          -  History of uncontrolled or unstable cardiovascular, respiratory, hepatic,
             gastrointestinal, endocrine, hematopoietic, psychiatric and/or neurological disease
             in the past 3 months

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease or surgery, which by the judgment of the Investigator, may increase a
             subject's risk of gastrointestinal bleeding or interfere with absorption of study
             drug (e.g., peptic or gastric ulcer disease, severe gastritis, history of
             gastrointestinal surgery).

          -  Any major surgery within 12 weeks of study drug administration

          -  History of significant head injury within the last 2 years, including subjects with
             base of skull fractures

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>December 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
